According to the latest Nielsen convenience store report, the market share of Vuse, an e-cigarette brand under Renault, has increased from 41.5% in the previous report to 42.7%, while Juul's market share has decreased from 26.4% to 25.6%.
Over the past 12 months, Vuse held a market share of 36.6% while Juul held a market share of 29.5%, according to data analysis conducted by Nielsen, which covers up to February 25th of this year.
NJOY, ranked third, maintained its position with 2.7% while Fontem Ventures' blu eCigs held steady at 1.4%.
On March 3rd, Altria announced that it had exchanged its 35% stake in Juul for exclusive intellectual property patents related to Juul's heated tobacco products. Following this, Altria acquired NJOY for $2.75 billion in cash.
According to the latest report, Juul's market share has decreased by 50.2%, to 25.7%, compared to a report from August 10, 2019.
In comparison, the sales growth of each brand from August 10th, 2019 to February of this year is as follows:
Renault's Vuse: Up 34%.
NJOY's stock has fallen by 8.7%.
blu eCigs experienced a 39.5% decrease in value.
Japan Tobacco's logic: Decreased by 4.9%.
In May 2019, Juul held a dominant 74.6% share of the electronic cigarette market in the United States. However, Nielsen's data did not include sales from e-cigarette stores, which could account for over 40% of all electronic cigarette product sales.
References:
The brand Vuse is continuing to increase its market share at the expense of its rival Juul.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
